Trump Administration Announces Plan to Lower Drug Prices

May 15, 2018

President Trump announced a new plan May 11 to lower drug prices and reduce out-of-pocket costs, which includes several strategies that affect independent community pharmacy.

“President Trump announced a program Friday that will impact community pharmacists and the patients they serve—an advocacy win for NCPA years in the making,” according to an announcement from the National Community Pharmacists Association (NCPA). “The Blueprint to Lower Drug Prices (titled “American Patients First“) is a direct response to NCPA’s longstanding advocacy and is a positive step forward in NCPA’s battle against DIR fees.”

The 39-page blueprint, American Patients First, includes several plans that affect independent pharmacies, including “potential policy approaches for applying some manufacturer rebates and all pharmacy price concessions to the price of a drug at the point-of-sale.”

The plan also calls for prohibiting clauses in Medicare Part D contracts that prevent pharmacists from telling patients when paying out-of-pocket is cheaper than using insurance.

In a statement released the same day, the U.S. Food and Drug Administration (FDA) outlined its efforts to streamline biosimilar approvals and remove barriers for generic drug development, which Trump’s new plan calls for.

The plan also discusses requiring pharmacy benefits managers (PBMs) to register as fiduciaries to ensure they act in the best interests of patients.

View the American Patients First fact sheet.